𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Stem cells for ischemic brain injury: A critical review

✍ Scribed by Terry C. Burns; Catherine M. Verfaillie; Walter C. Low


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
601 KB
Volume
515
Category
Article
ISSN
0021-9967

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

No effective therapy is currently available to promote recovery following ischemic stroke. Stem cells have been proposed as a potential source of new cells to replace those lost due to central nervous system injury, as well as a source of trophic molecules to minimize damage and promote recovery. We undertook a detailed review of data from recent basic science and preclinical studies to investigate the potential application of endogenous and exogenous stem cell therapies for treatment of cerebral ischemia. To date, spontaneous endogenous neurogenesis has been observed in response to ischemic injury, and can be enhanced via infusion of appropriate cytokines. Exogenous stem cells from multiple sources can generate neural cells that survive and form synaptic connections after transplantation in the stroke‐injured brain. Stem cells from multiple sources cells also exhibit neuroprotective properties that may ameliorate stroke deficits. In many cases, functional benefits observed are likely independent of neural differentiation, although the exact mechanisms remain poorly understood. Future studies of neuroregeneration will require the demonstration of function in endogenously born neurons following focal ischemia. Further, methods are currently lacking to demonstrate definitively the therapeutic effect of newly introduced neural cells. Increased plasticity following stroke may facilitate the functional integration of new neurons, but the loss of appropriate guidance cues and supporting architecture in the infarct cavity will likely impede the restoration of lost circuitry. Thus careful investigation of the mechanisms underlying trophic benefits will be essential. Evidence to date suggests that continued development of stem cell therapies may ultimately lead to viable treatment options for ischemic brain injury. J. Comp. Neurol. 515:125–144, 2009. Β© 2009 Wiley‐Liss, Inc.


πŸ“œ SIMILAR VOLUMES


Hypoxic-ischemic brain injury activates
✍ Darryl K. Miles; Steven G. Kernie πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 802 KB

## Abstract Although the phenomenon of ongoing neurogenesis in the hippocampus is well described, it remains unclear what relevance this has in terms of brain self‐repair following injury. In a highly regulated developmental program, new neurons are added to the inner granular cell layer of the den

Stem cell therapy for neonatal brain inj
✍ Luigi Titomanlio; Annemieke Kavelaars; Jeremie Dalous; Shyamala Mani; Vincent El πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 313 KB πŸ‘ 2 views

## Abstract Cerebral palsy is a major health problem caused by brain damage during pregnancy, delivery, or the immediate postnatal period. Perinatal stroke, intraventricular hemorrhage, and asphyxia are the most common causes of neonatal brain damage. Periventricular white matter damage (periventri

Hematopoietic cells as hepatocyte stem c
✍ Snorri S. Thorgeirsson; Joe W. Grisham πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 188 KB

The authors reviewed 77 published reports available before August 1, 2005 that examined the ability of hematopoietic cells to generate hepatocytes in the liver. A list of these publications and a synopsis of each are available on-line. We interpret the evidence provided by this data set to suggest t

Minocycline: A neuroprotective agent for
✍ Kathryn M. Buller; Michelle L. Carty; Hanna E. Reinebrant; Julie A. Wixey πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 135 KB πŸ‘ 2 views

## Abstract Minocycline is a second‐generation tetracycline and a potential neuroprotective intervention following brain injury. However, despite the recognized beneficial effects of minocycline in a multitude of adult disease states, the clinical application of minocycline in neonates is contentio